NCT07034391RECRUITINGanonymous

A Phase II Single-Arm Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Sponsor

Source record

China Medical University, China

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

denosumab combined anti-PD-1 inhibitor with chemotherapy

Indication / condition

AI-normalized

Non-Small Cell Lung Cancer

Intervention

Source record

denosumab combined anti-PD-1 inhibitor with chemotherapy

Related intelligence directories

Indication directory: Non-Small Cell Lung Cancer Modality directory: small molecule Target directory: denosumab combined anti-PD-1 inhibitor with chemotherapy

Source & freshness

Source record

NCT ID

NCT07034391

Original source

ClinicalTrials.gov

Source last updated

Jun 24, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07034391

Title

A Phase II Single-Arm Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Sponsor

China Medical University, China

Status

RECRUITING

Phase

PHASE2

Condition raw

Non-Small Cell Lung Cancer

Condition normalized

Non-Small Cell Lung Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

denosumab combined anti-PD-1 inhibitor with chemotherapy

Target normalized

denosumab combined anti-PD-1 inhibitor with chemotherapy

Interventions

denosumab combined anti-PD-1 inhibitor with chemotherapy

Public preview

Source record

This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Single-Arm Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT07034391

Status

RECRUITING

Phase

PHASE2

Sponsor

China Medical University, China

Executive brief

Investment-Ready Snapshot

This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1/PD-L1 inhibitor in locally advanced or metastatic NSCLC.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJun 24, 2025

Internal syncJun 19, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07034391

Indication

Non-Small Cell Lung Cancer

Modality

small molecule

Target

denosumab combined anti-PD-1 inhibitor with chemotherapy

Intervention

denosumab combined anti-PD-1 inhibitor with chemotherapy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.